CSI Market
Sign In | Register

Spectrum Pharmaceuticals Inc (SPPI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SPPI quarterly Cash Flow →
Looking at cash flow data from Spectrum Pharmaceuticals Inc through Dec 31 2018 provides insight into Dec 31 2022's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2018)
Operating Activities
Income-153.51
Depreciation & amortization0.25
Amortization of Other Assets0.20
Increase (Decrease) in Deferred Revenue0.00
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-9.23
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation8.49
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.08
Fair Value Of Common Stock Issued For Drug License-
Gain Loss On Derivative Instruments Net Pretax-
Increase Decrease In Accrued Drug Development Costs-
Increase Decrease In Landlord Contributions To Tenant Improvements-
Increase Decrease In Deferred Tax Assets-
Change In Fair Value Of Acquisition Contingencies-
Accretion Of Discount-
Write Off Of Deferred Debt Issuance Cost-
Increase Decrease In Deferred Taxes-
Increase Decrease In Deferred Tax Liabilities-
Change Of Business Acquisition Contingent Consideration At Fair Value-
Operating Lease Noncash Lease Expense0.71
Debt Securities Available For Sale Unrealized Gain Loss-
Available for Sale Securities Unrealized Gains Losses Tax-
Debt Securities Available for Sale Securities Unrealized Gains Losses Tax-
Equity Securities Fv Ni Realized Gain Loss1.35
Asset Impairment And Write Off Charges-
Marketable Securities Unrealized Gain Loss2.92
Income taxes0.00
Gain (Loss) on Sale of Investments0.02
Accounts Receivable-23.70
Accounts Payable0.00
Accrued Expense0.00
Recognition of Deferred Revenue0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.80
Other Working Capital-1.50
Other Noncash Income (Expense)0.11
Other net0.00
Payments for (Proceeds from) Other Operating Activities74.93
Discontinued operations2.70
Net Cash flow from Operating Activities-96.99
Investing Activities
Capital Expenditures-0.27
Sale of Capital Items0.00
Proceeds from Maturities, Repayments and Calls of Trading Securities Held-for-investment5.97
Payments to Acquire Available-for-sale Securities, Equity-32.41
Real Estate Investments0.00
Redemption Of Certificates Of Deposit-
Change In Value Of Marketable Securities Financing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments for Previous Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Proceeds from Life Insurance Policies0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-26.72
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings28.70
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock46.89
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.69
Proceeds From Issuance Of Common Stock And Warrants Net Of Related Offering Costs And Expenses-
Proceeds From Issuance Of Common Stock To Employees Shelf Down-
Repurchase Of Stock Options Pursuant To Tender Offer-
Repurchase Of Shares To Satisfy Minimum Tax Withholding For Restricted Stock Vesting-
Proceeds From Issuance Of Convertible Senior Notes Net Of Issuance Costs-
Deferred Finance Costs Net-
Proceeds From Issuance Of Common Stock And Warrants-
Issuance Of Common Stock Per Exercise Of Put Call Option-
Proceeds Received From Employees Relatedto Sharebased Payment Awards-
Proceeds Received From Employees Related To Sharebased Payment Awards-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Operating Lease Payments1.69
Capital Expenditures Incurred But Not Yet Paid-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities75.59
Effect of exchange rate on cash flow-0.06
Discontinued operations0.00
Free Cash Flow-97.26
Total Cash Flow-48.17
4 historic quarters locked

Sign in to unlock the full Spectrum Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Spectrum Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000831547-23-000012

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License